Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects ...

AstraZeneca stock rose 230p (1.64 per cent) to 14,118 per share within an hour of the London stockmarket opening this morning with AZ basking in the heat of a near-£216 billion market cap.

Astrazeneca boss Pascal Soriot was handed his largest ever pay package last year - taking his total earnings at the pharma giant to £168million.

AstraZeneca stock rose moderately Tuesday morning on better-than-expected sales and profit in the fourth quarter.

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market ...

AstraZeneca received FDA approval for Calquence with venetoclax, creating the first all oral, fixed duration regimen for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. The ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. Its would-be partner is an American biotech that has earned a lot of attention lately. A ...

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the ...

That morning, U.K. newspaper The Times published an article stating that AstraZeneca CEO Pascal Soriot aims to move the company's stock market listing onto our shores (ADSes are certificates ...

AstraZeneca AZN stock has risen 15% so far this year compared with an increase of 0.2% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.